Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015

Philip A. Thompson, Hagop M. Kantarjian, Jorge E. Cortes

Research output: Contribution to journalReview article

Abstract

Few neoplastic diseases have undergone a transformation in a relatively short period like chronic myeloid leukemia (CML) has in the last few years. In 1960, CML was the first cancer in which a unique chromosomal abnormality was identified and a pathophysiologic correlation suggested. Landmark work followed, recognizing the underlying translocation between chromosomes 9 and 22 that gave rise to this abnormality and, shortly afterward, the specific genes involved and the pathophysiologic implications of this novel rearrangement. Fast forward a few years and this knowledge has given us the most remarkable example of a specific therapy that targets the dysregulated kinase activity represented by this molecular change. The broad use of tyrosine kinase inhibitors has resulted in an improvement in the overall survival to the point where the life expectancy of patients today is nearly equal to that of the general population. Still, there are challenges and unanswered questions that define the reasons why the progress still escapes many patients, and the details that separate patients from ultimate cure. In this article, we review our current understanding of CML in 2015, present recommendations for optimal management, and discuss the unanswered questions and what could be done to answer them in the near future.

Original languageEnglish (US)
Pages (from-to)1440-1454
Number of pages15
JournalMayo Clinic Proceedings
Volume90
Issue number10
DOIs
StatePublished - Oct 2015
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosomes, Human, Pair 22
Chromosomes, Human, Pair 9
Life Expectancy
Chromosome Aberrations
Protein-Tyrosine Kinases
Phosphotransferases
Therapeutics
Survival
Population
Genes
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015. / Thompson, Philip A.; Kantarjian, Hagop M.; Cortes, Jorge E.

In: Mayo Clinic Proceedings, Vol. 90, No. 10, 10.2015, p. 1440-1454.

Research output: Contribution to journalReview article

Thompson, Philip A. ; Kantarjian, Hagop M. ; Cortes, Jorge E. / Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015. In: Mayo Clinic Proceedings. 2015 ; Vol. 90, No. 10. pp. 1440-1454.
@article{4e3c4787bca4471eabeca8fb0d1eab85,
title = "Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015",
abstract = "Few neoplastic diseases have undergone a transformation in a relatively short period like chronic myeloid leukemia (CML) has in the last few years. In 1960, CML was the first cancer in which a unique chromosomal abnormality was identified and a pathophysiologic correlation suggested. Landmark work followed, recognizing the underlying translocation between chromosomes 9 and 22 that gave rise to this abnormality and, shortly afterward, the specific genes involved and the pathophysiologic implications of this novel rearrangement. Fast forward a few years and this knowledge has given us the most remarkable example of a specific therapy that targets the dysregulated kinase activity represented by this molecular change. The broad use of tyrosine kinase inhibitors has resulted in an improvement in the overall survival to the point where the life expectancy of patients today is nearly equal to that of the general population. Still, there are challenges and unanswered questions that define the reasons why the progress still escapes many patients, and the details that separate patients from ultimate cure. In this article, we review our current understanding of CML in 2015, present recommendations for optimal management, and discuss the unanswered questions and what could be done to answer them in the near future.",
author = "Thompson, {Philip A.} and Kantarjian, {Hagop M.} and Cortes, {Jorge E.}",
year = "2015",
month = "10",
doi = "10.1016/j.mayocp.2015.08.010",
language = "English (US)",
volume = "90",
pages = "1440--1454",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "10",

}

TY - JOUR

T1 - Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015

AU - Thompson, Philip A.

AU - Kantarjian, Hagop M.

AU - Cortes, Jorge E.

PY - 2015/10

Y1 - 2015/10

N2 - Few neoplastic diseases have undergone a transformation in a relatively short period like chronic myeloid leukemia (CML) has in the last few years. In 1960, CML was the first cancer in which a unique chromosomal abnormality was identified and a pathophysiologic correlation suggested. Landmark work followed, recognizing the underlying translocation between chromosomes 9 and 22 that gave rise to this abnormality and, shortly afterward, the specific genes involved and the pathophysiologic implications of this novel rearrangement. Fast forward a few years and this knowledge has given us the most remarkable example of a specific therapy that targets the dysregulated kinase activity represented by this molecular change. The broad use of tyrosine kinase inhibitors has resulted in an improvement in the overall survival to the point where the life expectancy of patients today is nearly equal to that of the general population. Still, there are challenges and unanswered questions that define the reasons why the progress still escapes many patients, and the details that separate patients from ultimate cure. In this article, we review our current understanding of CML in 2015, present recommendations for optimal management, and discuss the unanswered questions and what could be done to answer them in the near future.

AB - Few neoplastic diseases have undergone a transformation in a relatively short period like chronic myeloid leukemia (CML) has in the last few years. In 1960, CML was the first cancer in which a unique chromosomal abnormality was identified and a pathophysiologic correlation suggested. Landmark work followed, recognizing the underlying translocation between chromosomes 9 and 22 that gave rise to this abnormality and, shortly afterward, the specific genes involved and the pathophysiologic implications of this novel rearrangement. Fast forward a few years and this knowledge has given us the most remarkable example of a specific therapy that targets the dysregulated kinase activity represented by this molecular change. The broad use of tyrosine kinase inhibitors has resulted in an improvement in the overall survival to the point where the life expectancy of patients today is nearly equal to that of the general population. Still, there are challenges and unanswered questions that define the reasons why the progress still escapes many patients, and the details that separate patients from ultimate cure. In this article, we review our current understanding of CML in 2015, present recommendations for optimal management, and discuss the unanswered questions and what could be done to answer them in the near future.

UR - http://www.scopus.com/inward/record.url?scp=84955415070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955415070&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2015.08.010

DO - 10.1016/j.mayocp.2015.08.010

M3 - Review article

C2 - 26434969

AN - SCOPUS:84955415070

VL - 90

SP - 1440

EP - 1454

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 10

ER -